Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess ...
Zealand and Roche's petrelintide peaks at 10.7% weight loss at its middle dose in Ph2, trailing Lilly's eloralintide at 20.1% ...
UniQure's shares were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy ...
The cash should give the Stockholm-based biotech a runway “well into 2029,” CEO Patrik Strömberg told Endpoints News in ...
Ex-Genentech AI leaders including NYU's Kyunghyun Cho launch health startup Ortet with a $500M commitment from Matt Holt's ...
At the end of 2027, BioNTech will exit factories in Idar-Oberstein and Marburg and a site in Tübingen that was ...
Beam Therapeutics sued YolTech's Yuxuan Wu & Zi Jun Wang and Serapha Bio for allegedly stealing trade secrets related to ...
ARCH and Population Health launch Somnivera with a $10.5M-upfront deal for an ex-China sleep drug from Jiangsu Nhwa.
Former House majority leader Eric Cantor has been chosen as PhRMA’s next CEO, according to two sources familiar ...
Breye Therapeutics raised €67.5M Series A; Aptadir raised €40M seed; Ascletis' ASC50 shows psoriasis results; Invivyd touts ...
Bio raises $48M Series A led by UPMC Enterprises & Ziff Capital to target Th17 cells via CD161+ antibody & CAD mRNA platforms ...
Fresenius Kabi will sell biosimilars for Humira, Stelara & Actemra directly to employers via Eversana's Waltz Health, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results